Table 5 Published study on SBRT for oligometastases from CRC
Author, design study, (reference) | Patients (n) | Lesions (n) | Dose (Gy/ fr) | FUP (m) | LC (%) | OS (%) | Median PFS (m) | Acute Toxicity ≥G3 | ||
|---|---|---|---|---|---|---|---|---|---|---|
1-year | 2-yeras | 1-year | 2-years | |||||||
Hoyer, Phase II (27) | 44 | - | 45 Gy/3 fr | 4.3 y | 90% | 79% | 67% | 38% | 6.5 | 48% |
Van der Pool, Phase I-II (28) | 20 | 31 | 37.5 Gy/3 fr | 26 m | 100% | 74% | 100% | 83% | 11 | 10% |
45 Gy/3 fr | ||||||||||
(2 pts) | ||||||||||
Kang, Retrospective (29) | 59 | 78 | 36–51 Gy/3 fr | 32 m | 85% | 66% | 82% | 66% | - | 3% |
14 Gy/1 fr | ||||||||||
Bae Retrospective (30) | 41 | 50 | 45–60 gy/3 fr | 28 m | 100% | 85% | 85% | 70% | - | 7% |
Current Study | 82 | 112 | 48 Gy/4 fr | 24m | 85% | 70% | 85% | 65% | 14m | 0% |
60–75 Gy/3 fr | 97% | 92% | ||||||||